|Articles|March 28, 2011

HIT Press Club AJMC - Dr. Sachin Jain Delivers the Closing Remarks

Dr. Sachin Jain, closes the Healthcare Innovations and HIT Q&A Session at the National Press Club in Washington, DC.

Dr. Sachin Jain, Office of the National Coordinator for HIT, closes the Healthcare Innovations and HIT Q&A Session at the National Press Club in Washington, DC.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

HIT Press Club AJMC - Dr. Sachin Jain Delivers the Closing Remarks

Related Content

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO

3 Considerations for Oncology Pharmacy Care Delivery: Minhee Kang, PharmD

UCART22 Advances to Phase 2 Following Encouraging Phase 1 Results in R/R B-Cell ALL: Nitin Jain, MD

The Oncology Care Model: A Decade of Transformation

Trending on AJMC

emtelligent Turns Unstructured Clinical Data Into Actionable Insights

Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

HIT Press Club AJMC - Dr. Sachin Jain Delivers the Closing Remarks

Related Content

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO

3 Considerations for Oncology Pharmacy Care Delivery: Minhee Kang, PharmD

UCART22 Advances to Phase 2 Following Encouraging Phase 1 Results in R/R B-Cell ALL: Nitin Jain, MD

The Oncology Care Model: A Decade of Transformation

Trending on AJMC

emtelligent Turns Unstructured Clinical Data Into Actionable Insights

Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Real-World Data Show MASH Progresses Faster Than Trials Suggest